The European Medicines Agency’s scientific committee will investigate a possible link between glitazone therapies and macular oedema, the agency announced on Thursday.The CHMP investigation comes after the EMEA received reports of cases of macular oedema in patients taking GlaxoSmithKline’s Avandia/Avandamet (rosiglitazone) and Takeda and Lilly’s Actos (pioglitazone).A spokeswoman for the EMEA told APM that since 2000 the agency had been alerted to 35 cases in patients taking pioglitazone and 28 on rosiglitazone.
